...
首页> 外文期刊>British journal of neurosurgery >Proteomic analysis of gliomas.
【24h】

Proteomic analysis of gliomas.

机译:胶质瘤的蛋白质组学分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Primary malignant brain tumours (anaplastic glioma and glioblastoma) display heterogenous histopathology and diverse genetic abnormalities. These tumours remain incurable with no significant improvement in median survival times in the last 20 years, despite significant technological advances in surgery and radiotherapy, and mechanistic insights into their aetiology. Recent clinical trials suggest molecular characterization of tumours is essential in guiding both therapy and predicting prognosis. Genetic insight into tumour biology and increasingly proteomic technology has opened new avenues for novel applied clinical research. Protein expression in human malignant glioma and matched normal brain tissues can now be reliably analysed using quantitative proteomic techniques, the most accessible of which is two-dimensional gel electrophoresis (2DGE) and matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry from which differentially expressed proteins can be identified andcharacterized. The potential of using differential proteomic profiling in gliomas to identify prognostic markers and to gain insight into tumour biology is currently being investigated. The current status of proteomic technology, its application to gliomas and the utility of such translational studies is reviewed.
机译:原发性恶性脑肿瘤(间变性神经胶质瘤和胶质母细胞瘤)表现出异质的组织病理学和多种遗传异常。尽管在手术和放疗方面取得了重大技术进步,并且对病因学有了机械学见识,但这些肿瘤仍无法治愈,在过去20年中中位生存时间没有明显改善。最近的临床试验表明,肿瘤的分子表征对于指导治疗和预测预后至关重要。对肿瘤生物学和越来越多的蛋白质组学技术的遗传见解为新颖的应用临床研究开辟了新途径。现在可以使用定量蛋白质组学技术可靠地分析人类恶性神经胶质瘤和匹配的正常脑组织中的蛋白质表达,其中最容易获得的是二维凝胶电泳(2DGE)和基质辅助激光解吸电离飞行时间(MALDI-TOF)质谱分析,可以从中鉴定和表征差异表达的蛋白质。目前正在研究在神经胶质瘤中使用差异蛋白质组学分析来鉴定预后标记和深入了解肿瘤生物学的潜力。综述了蛋白质组学技术的现状,其在神经胶质瘤中的应用以及这种转化研究的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号